Clinical trials: Anlotinib
Adenoid Cystic Carcinoma
Neoadjuvant Anlotinib and Epirubicin for T4 Sinonasal Adenoid Cystic Carcinoma
T4 stage sinonasal adenoid cystic carcinoma (SNACC) is a rare but aggressive cancer in the nasal cavity and sinuses. These tumors often invade the skull base, eye socket, or brain covering (dura), making complete surgical removal…
- Trial name
- NAET4-SNACC (NCT07616141)
- Testing
- Anlotinib + Epirubicin
- Where
- 5 sites in China
- Volunteers
- 76 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Advanced Esophageal Squamous Cell Carcinoma
Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma
Penpulimab plus chemotherapy with or without Anlotinib as first-line therapy for patients with advanced esophageal squamous cell carcinoma (Answer): A randomized two-arm clinical study.
- Trial name
- ANSWER (NCT05214222)
- Testing
- Anlotinib/Penpulimab/Chemotherapy, Penpulimab/Chemotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Stage III Non-small-cell Lung Cancer
A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer
Stage III non-small-cell lung cancer (NSCLC) is seen in a relatively heterogeneous group of patients with ipsilateral mediastinal (N2) lymph node involvement. The relative roles of different treatment modalities are not clear.
- Trial name
- NCT04181372
- Testing
- Anlotinib hydrochloride, platinum-based chemotherapy medicine
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Liver Neoplasms
Anlotinib for Hepatocellular Carcinoma
The purpose of this study is to observe and explore the effect of single or combined treatment of arotinib on the survival and prognosis of patients with advanced liver cancer in the real world, and to summarize the treatment…
- Trial name
- AFHC (NCT04954521)
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 200 people
- Sponsor
- People's Hospital of Guangxi Zhuang Autonomous Region
MGMT-Unmethylated Glioblastoma
Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma.
This is a prospective, open-label single-arm, exploratory, two-stage design trial, aiming to investigate safety and efficacy of AK105 with anlotinib and radiotherapy adjuvant therapy in MGMT unmethylated newly diagnosed…
- Trial name
- NCT05033587
- Testing
- Anlotinib, AK105, Radiotherapy
- Where
- China
- Volunteers
- 28 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Breast Cancer
ADCb (Anlotinib/Docetaxel/Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast Cancer
DCb (docetaxel/carboplatin) regimens as Neoadjuvant Treatment for Triple-Negative Breast Cancer have been recommended by NCCN guideline.Combination of anti-angiogenesis inhibitors is expected to further improvePathologic Complete…
- Trial name
- NCT04975451
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Anqin Zhang
Cervical Cancer
AK105 Combined With Anlotinib in Patients With Cervical Cancer
The purpose of this study is to evaluate the efficacy and safety of AK105 (anti-PD-1 mab) combined with Anlotinib Hydrochloride in the treatment of persistent, recurrent and metastatic cervical cancer.
- Trial name
- NCT05137171
- Testing
- AK105 and anlotinib
- Where
- 2 sites in China
- Volunteers
- 36 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Lung Cancer
Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations
This study was a single-arm, open-label, phase II study of PD-1 monoclonal antibody combined with anlotinib in the treatment of advanced non-small cell lung cancer (NSCLC) with EGFR uncommon mutations.
- Trial name
- NCT04790409
- Testing
- sintilimab and anlotinib
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Zhejiang Cancer Hospital
Nonsmall Cell Lung Cancer
Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLC
Based on the need of clinical practice of maintenance therapy for advanced NSCLC and the reliable data of third-line treatment for non-small cell lung cancer, the investigators designed a clinical study of antinil hydrochloride…
- Trial name
- CSOAIMTOAN (NCT03769805)
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 83 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Gastric Cancer
Tislelizumab Combined With Anlotinib and Chemotherapy (XELOX) in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (TALENT)
This is a Phase 2, multi-cohort study to investigate safety, anti-tumor activity of the monoclonal antibody BGB A317 in combination with Anlotinib and standard chemotherapy as first-line treatment in Gastric, or Gastroesophageal…
- Trial name
- TALENT (NCT04963088)
- Testing
- BGB-A317, Anlotinib, Oxaliplatin
- Where
- China
- Volunteers
- 65 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Hepatocarcinoma
HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection
This is a single center, non-randomized, open, multi-cohort clinical, exploratory Phase II study, to evaluate the efficacy and safety of HAIC combined with TQB2450 and anlotinib as adjuvant therapy in hepatocellular carcinoma…
- Trial name
- NCT05311319
- Testing
- HAIC+TQB2450+Anlotinib
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Fudan University
Soft Tissue Sarcoma
Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard Treatment
Objective to evaluate the efficacy and safety of candonilimab combined with anlotinib in the treatment of progressive or metastatic soft tissue sarcoma that failed previous first-line standard therapy.
- Trial name
- NCT05926700
- Testing
- Candonilimab
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Extensive Small Cell Lung Cancer
A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)
A randomized, double-blind, controlled, multicenter phase III study of TQB2450 or placebo combined with Anlotinib, etoposide and carboplatin versus Etoposide and Carboplatin in subjects with extensive small cell lung cancer.
- Trial name
- NCT04234607
- Testing
- TQB2450, Anlotinib, Etoposide
- Where
- 26 sites in China
- Volunteers
- 738 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
ALK-positive, Locally Advanced or Metastatic (TNM Stage IIIB-IV) Non-small Cell Lung Cancer That Has Developed Resistance to Prior Treatment With Lorlatinib
Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive NSCLC
ALK TKIs, particularly second- and third-generation ALK TKIs, have significantly improved progression-free survival (PFS) in patients with advanced ALK-positive non-small cell lung cancer (NSCLC).
- Trial name
- NCT07671560
- Testing
- Combined group of ensatinib and arotinib
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Qiming Wang
Esophageal Squamous Cell Carcinoma (ESCC)
A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma
Esophageal squamous cell carcinoma (ESCC) is one of the malignant tumors with a high incidence worldwide, especially remaining persistently high in Asian regions.
- Trial name
- NCT07142421
- Testing
- Combination therapy (COMB)
- Where
- China
- Volunteers
- 35 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Breast Neoplasm Female
AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer
This trial used a multicentre, single-arm design in which patients were treated with AK105 plus Anlotinib Hydrochloride combined with albumin paclitaxel.
- Trial name
- NCT05244993
- Testing
- AK105, Anlotinib hydrochloride, Albumin Paclitaxel
- Volunteers
- 42 people
- Sponsor
- Liaoning Cancer Hospital & Institute
Advanced Solid Tumor
Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody
The main objective was to evaluate the safety and efficacy of anlotinib hydrochloride combined with pd-1 antibody second-line and above in the treatment of advanced solid tumors
- Trial name
- NCT03975036
- Testing
- Anlotinib, pd-1 antibody
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Henan Cancer Hospital
Non-small Cell Lung Cancer, EGFR Mutant Advanced Non-small Cell Lung Cancer
Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis
The goal of this clinical trial is to learn if the combination therapy with SKB264 and anlotinib works to treat EGFR-TKI-resistant, liver-metastatic non-squamous non-small cell lung cancer (NSCLC).
- Trial name
- NCT07545213
- Testing
- SKB264
- Where
- China
- Volunteers
- 27 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Platinum-resistant Ovarian Cancer
Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer
At present, the standard treatment for platinum-resistant ovarian cancer patients is platinum-free chemotherapy, with poor efficacy and tolerance.
- Trial name
- ANNIE (NCT04376073)
- Testing
- Niraparib, Anlotinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Jihong Liu
Extensive Stage Small Cell Lung Cancer
Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung Cancer
This is a the researchers launched a multicenter, prospective, single arm phase II clinical study, the group always had at least two cycle line standard platinum-based treatment and curative effect for SD, at least 6 months…
- Trial name
- NCT04933175
- Testing
- Fluzoparil, Anlotinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Liu Zhenhua